Immatics N.V.
General ticker "IMTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $714.1M (TTM average)
Immatics N.V. follows the US Stock Market performance with the rate: 58.2%.
Estimated limits based on current volatility of 2.8%: low 9.75$, high 10.31$
Factors to consider:
- Total employees count: 85 as of 2020
- Current price 17.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.37$, 9.79$]
- 2025-12-31 to 2026-12-31 estimated range: [3.90$, 8.66$]
Financial Metrics affecting the IMTX estimates:
- Positive: with PPE of 50.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -21.63 <= 0.01
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 2.14
- Negative: negative Industry operating income (median)
Short-term IMTX quotes
Long-term IMTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €172.83MM | €54.00MM | €155.84MM |
| Operating Expenses | €142.88MM | €155.72MM | €194.45MM |
| Operating Income | €29.95MM | €-101.72MM | €-38.62MM |
| Non-Operating Income | €12.08MM | €4.73MM | €59.96MM |
| Interest Expense | €1.04MM | €0.83MM | €0.89MM |
| R&D Expense | €106.78MM | €118.66MM | €148.08MM |
| Income(Loss) | €42.04MM | €-96.99MM | €21.35MM |
| Taxes | €4.55MM | €0.00MM | €6.13MM |
| Profit(Loss)* | €37.51MM | €-99.34MM | €15.22MM |
| Stockholders Equity | €213.16MM | €225.08MM | €574.84MM |
| Assets | €407.82MM | €509.96MM | €696.15MM |
| Operating Cash Flow | €100.13MM | €18.23MM | €-158.03MM |
| Capital expenditure | €6.21MM | €30.96MM | €16.48MM |
| Investing Cash Flow | €-209.79MM | €-31.39MM | €-152.39MM |
| Financing Cash Flow | €123.71MM | €84.52MM | €319.68MM |
| Earnings Per Share** | €0.56 | €-1.23 | €0.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.